Company Overview
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Why Investors Should Care
Revenue has grown at a 28.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $105.97M (+38.9% YoY); net profit $-81.13M.
- Trailing 12 Months Year-on-year growth — revenue -91.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.43% |
| 1 Year: | -91.10% |
Stock Price Performance
| 1 Year: | +109.40% |
| 6 Months: | +21.22% |
| 3 Months: | +21.42% |
| 1 Month: | +26.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross8d ago
- RSI (14)59.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZYME Zymeworks Inc. R2KR3KPHARMA | 29.19 | -21.00 | $2.07B | 0.00% | -30.42% | -42.02% | 28.43% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 4.39M | 1.92M | 5.44M | 2.63M | 35.58M | 7.00M | 16.51M | 10.03M | 19.24M | 16.00M | - | 27.11M | 48.73M | 27.61M | 2.52M | 2.41M | 4.59M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.74M | 49.35M | 49.68M | 46.63M | 49.56M | - |
| Operating Income | - | - | -60.96M | -72.69M | -65.82M | -50.36M | -27.28M | -54.11M | -33.24M | -37.80M | -42.89M | -34.20M | - | -25.63M | -623.00K | -22.06M | -44.12M | -47.15M | -42.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.84M | 2.59M | -19.48M | -42.11M | -41.44M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 2.07M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.14M | 2.13M | -18.27M | -41.48M | -46.35M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 496.00K | -186.00K | 1.34M | -270.00K | -2.19M | - |
| Net Income | -44.59M | -67.52M | -60.58M | -72.62M | -64.62M | -47.85M | -24.35M | -51.15M | -28.69M | -31.65M | -37.69M | -29.85M | - | -22.64M | 2.32M | -19.60M | -41.21M | -44.16M | -45.02M |
| Diluted EPS | - | - | -1.25 | -1.19 | -0.97 | -0.72 | -0.37 | -0.76 | -0.41 | -0.42 | -0.49 | -0.39 | - | -0.30 | 0.03 | -0.26 | -0.55 | -0.59 | -0.62 |
| R&D Expense | - | - | 49.89M | 62.51M | 56.02M | 37.10M | 45.91M | 39.41M | 32.77M | 32.04M | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 38.95M | - | 412.48M | 76.01M | 76.30M | 105.97M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 282.00M | 214.02M | 196.12M | 198.50M |
| Operating Income | -187.47M | - | 130.49M | -138.01M | -119.82M | -92.53M |
| EBITDA | - | - | 142.49M | -120.70M | -108.62M | -81.42M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | 135.23M | -119.24M | -116.61M | -79.75M |
| Tax Provision | - | - | 10.89M | -568.00K | 6.08M | 1.38M |
| Net Income | -180.55M | - | 124.34M | -118.67M | -122.69M | -81.13M |
| Diluted EPS | -3.58 | - | 1.90 | -1.72 | -1.62 | -1.08 |
| R&D Expense | 171.20M | 199.75M | 208.60M | 143.62M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 648.73M | 580.88M | 463.09M | 346.53M |
| Current Assets | - | - | - | 544.71M | 412.93M | 300.45M | 248.77M |
| Cash & Equivalents | - | - | - | 400.91M | 157.56M | 66.10M | 41.16M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 33.40M | 19.48M | 55.81M | 4.64M |
| Total Liabilities | - | - | - | 155.77M | 116.07M | 124.32M | 78.03M |
| Current Liabilities | - | - | - | 95.62M | 55.76M | 88.29M | 42.32M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 28.11M | 26.72M | 18.51M | 18.27M |
| Total Equity | 245.68M | 409.92M | - | 492.96M | 464.81M | 338.77M | 268.50M |
| Shares Outstanding | - | - | - | 63.06M | 70.12M | 68.96M | 75.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -151.40M | - | 144.11M | -118.32M | -110.06M | -33.01M |
| Investing Cash Flow | -43.44M | - | -53.85M | -207.25M | 38.76M | 26.66M |
| Financing Cash Flow | 308.98M | - | 108.58M | 81.87M | -20.44M | -18.56M |
| Capital Expenditure | -4.31M | - | -13.12M | -4.08M | -3.07M | -2.35M |
| Free Cash Flow | -155.71M | - | 130.98M | -122.40M | -113.12M | -35.36M |
| Net Change in Cash | - | - | 198.84M | -243.71M | -91.74M | -24.90M |
| Share Buybacks | - | - | 0 | 0 | 30.05M | 41.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -481.3% | - | 31.6% | -181.6% | -157.0% | -87.3% |
| Net Margin % | -463.5% | - | 30.1% | -156.1% | -160.8% | -76.6% |
| ROE % | -44.0% | - | 25.2% | -25.5% | -36.2% | -30.2% |
| ROCE % | - | - | 23.6% | -26.3% | -32.0% | -30.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 36.46% | 22.97M | $649.37M |
| 2 | Rubric Capital Management LP | 11.11% | 7.00M | $197.89M |
| 3 | Blackrock Inc. | 6.75% | 4.25M | $120.18M |
| 4 | Perceptive Advisors Llc | 6.64% | 4.18M | $118.25M |
| 5 | BVF Inc. | 5.79% | 3.65M | $103.16M |
| 6 | Morgan Stanley | 3.54% | 2.23M | $63.08M |
| 7 | BNP Paribas Asset Management Holding S.A. | 2.83% | 1.78M | $50.35M |
| 8 | Vanguard Capital Management LLC | 2.47% | 1.56M | $44.07M |
| 9 | Assenagon Asset Management S.A. | 1.99% | 1.25M | $35.39M |
| 10 | Nextech Invest, Ltd. | 1.77% | 1.11M | $31.49M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZYME
Zymeworks (ZYME), What Is Behind The Renewed Attention?
Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putting fresh attention on what this decision…
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab
Zymeworks (NASDAQ:ZYME) shares climbed nearly 4. 0% in pre-market trading as investors positioned themselves ahead of an important U.
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherap…
ZYME — Frequently Asked Questions
What is the current share price of Zymeworks Inc. (ZYME)?
As of 2026-09-07 16:24 PDT, Zymeworks Inc. (ZYME) trades at $29.19 on NasdaqGS. Its 52-week range is $13.94 to $31.05.
What is the market capitalisation of ZYME?
Zymeworks Inc. (ZYME) has a market capitalisation of $2.07B on NasdaqGS.
What is the P/E ratio of ZYME?
ZYME trades at a trailing price-to-earnings (P/E) ratio of -21.00. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 10.74.
What is the return on equity (ROE) of ZYME?
ZYME has a return on equity (ROE) of -42.02%. Its return on capital employed (ROCE) is -30.42%.
Is ZYME a good stock to buy?
This page provides a data-driven analysis of Zymeworks Inc. (ZYME), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.